Literature DB >> 28891398

Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.

Simon Boeke1,2, Daniela Thorwarth2,3, David Mönnich2,3, Christina Pfannenberg4, Gerald Reischl5, Christian La Fougère6, Konstantin Nikolaou4, Paul-Stefan Mauz7, Frank Paulsen1, Daniel Zips1,3, Stefan Welz1.   

Abstract

INTRODUCTION: A previous pattern-of-failure study has suggested that up to 50% of the loco-regional failures (LRF) in head and neck squamous cell carcinoma (HNSCC) occur outside the initial hypoxic volume determined by [18F]-fluoromisonidazole-PET ([18F]-FMISO-PET). The aim of the present analysis was to correlate spatial patterns of failure with respect to the pretherapeutic dynamic [18F]-FMISO-PET/CT in HNSCC after radiochemotherapy (RCT).
MATERIAL AND METHODS: Within a running phase 2 trial using [18F]-FMISO-PET imaging prior to RCT in HNSCC patients (n = 54), we have observed so far 11 LRF with a minimum follow-up of 12 months. For nine patients, LRF imaging (CT or [18F]-FDG-PET/CT) for pattern-of-failure analysis was available. Analysis included the static 4-h hypoxic subvolume (VH) as well as a M-parameter volume (VM), which is derived from modeling of dynamic PET. Deformable image registration of the CT scan with the recurrent tumor to the pre-treatment [18F]-FMISO-PET/CT and the planning CT was done to quantify the hypoxic subvolumes compared to the recurrent tumor volume. Moreover, a point-of-origin analysis was performed.
RESULTS: A total of five local, two regional and two loco-regional recurrences were detected. After deformable image registration of the CT scan with the recurrent tumor to the pre-treatment [18F]-FMISO-PET/CT and the planning CT, a significant overlap of the recurrence volume with [18F]-FMISO-positive subvolumes in the initial gross tumor volume (GTV) was observed. Median overlap of 40.2%, range 9.4-100.0%, for VH and 49.0%, range 4.4-96.4%, for VM was calculated. The point-of-origin analysis showed median distances of 0.0 mm, range 0.0-11.3 mm to VH and 8.6 mm, range 0.0-15.5 mm to VM, respectively.
CONCLUSIONS: Our data suggest that loco-regional recurrences after RCT originate from the initial GTV (primary tumor and/or lymph node metastases) containing hypoxic subvolumes, which supports the concept of hypoxia imaging-based dose escalation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28891398     DOI: 10.1080/0284186X.2017.1372626

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  4 in total

Review 1.  Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.

Authors:  Sonja Stieb; Afroditi Eleftheriou; Geoffrey Warnock; Matthias Guckenberger; Oliver Riesterer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-20       Impact factor: 9.236

2.  Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.

Authors:  Nicole Wiedenmann; Hatice Bunea; Hans C Rischke; Andrei Bunea; Liette Majerus; Lars Bielak; Alexey Protopopov; Ute Ludwig; Martin Büchert; Christian Stoykow; Nils H Nicolay; Wolfgang A Weber; Michael Mix; Philipp T Meyer; Jürgen Hennig; Michael Bock; Anca L Grosu
Journal:  Radiat Oncol       Date:  2018-08-29       Impact factor: 3.481

Review 3.  Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.

Authors:  Franziska Eckert; Kerstin Zwirner; Simon Boeke; Daniela Thorwarth; Daniel Zips; Stephan M Huber
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

4.  Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma - Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes.

Authors:  Marta Bogowicz; Matea Pavic; Oliver Riesterer; Tobias Finazzi; Helena Garcia Schüler; Edna Holz-Sapra; Leonie Rudofsky; Lucas Basler; Manon Spaniol; Andreas Ambrusch; Martin Hüllner; Matthias Guckenberger; Stephanie Tanadini-Lang
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.